MIAMI, July 14, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc., (OTC Pink: TPIA) ("Mycotopia" or the “Company”) announced today that on July 13, 2021 Wesana Health Holdings Inc. (“Wesana”) (CSE: ...

VANCOUVER, BC / ACCESSWIRE / February 10, 2023 / Cube Psytech Holdings Inc. (the "Company" or "CUBE"), a biopharmaceutical and biotechnology company focused on the research and development of ...

TEL AVIV, Israel, Feb. 20, 2020 /PRNewswire/ -- The world's leading cannabis and psychedelic medicine scientists and researchers, investors, industry leaders and opinion makers will gather in Tel Aviv ...

On Tuesday, Wesana Health Holdings WESA, a life science company that champions the development of psychedelics and other medicines for the treatment of traumatic brain injury, announced a definitive ...

OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Ltd, a private, clinical-stage biotechnology company developing rapid-acting, short-duration psychedelic medicines for neuropsychiatric conditions, ...

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT ...

Upsized and oversubscribed Series B financing brings healthcare and science focused venture capital Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in ...

Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and long-lasting antidepressant effect for up to three months after dosing. BPL-003 was ...

One year after raising a modest £3 million round, Beckley Psytech scored £58 million ($80 million) to get two psychedelics-based programs through the clinic. With the funding, the Oxford, U.K.-based ...

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its ...